Alcoholic Cardiomyopathy Mortality in the United States (1999-2024): Trends, Disparities, and Opportunities for Prevention
- 1Internal Medicine, Ascension Saint Agnes Hospital, Baltimore, USA
- 2Emergency Department, Dhading District Hospital, Dhading, NPL
Abstract
Aim: This study aimed to characterize long-term US mortality from alcoholic cardiomyopathy (ACM), compare its trajectory with other major cardiomyopathy subtypes, and identify demographic and geographic disparities relevant to cardiovascular prevention.
Methods: We conducted a serial cross-sectional analysis of Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) underlying-cause-of-death data from 1999 to 2024. Cardiomyopathy deaths were identified using ICD-10 codes I42.0, I42.1, I42.2, I42.5, I42.6, I42.8, and I42.9. Annual age-adjusted mortality rates (AAMRs) were assessed overall and by sex; age-specific crude death rates (CDRs) were recalculated for ages 15-44, 45-64, and 65-84 years. ACM mortality was also examined by race and state.
Results: From 1999 to 2024, AAMRs declined for dilated cardiomyopathy (1.965 to 0.716 per 100,000; -63.6%), unspecified cardiomyopathy (7.196 to 3.155; -56.2%), and other hypertrophic cardiomyopathy (0.450 to 0.228; -49.2%). ACM declined less, from 0.199 to 0.144 (-27.7%), with an increase during the early 2020s. Male ACM AAMR declined from 0.408 to 0.209 but remained nearly fourfold the female rate in 2024 (0.054). Mortality was concentrated among middle-aged and older males; American Indian or Alaska Native individuals had the highest population-based ACM mortality, and Alaska had the highest pooled state AAMR in 2018-2024.
Conclusion: ACM showed a smaller long-term mortality reduction than several major cardiomyopathy subtypes and persistent demographic and geographic disparities. Integrating cardiovascular prevention and heart failure care with recognition and treatment of harmful alcohol use may help reduce this potentially modifiable burden.
Related
- Alcoholic cardiomyopathy–related mortality in the United States, 1999–2024: temporal trends and sociodemographic and geographic disparities
- DBT Modulates Copper-Dependent Cuproptosis-Related Injury in Experimental Alcoholic Cardiomyopathy.
- Racial, sex, and geographic disparities in mortality involving stroke and chronic kidney disease: a CDC WONDER database analysis, 1999–2020
- The effect of regional disparities in access to rehabilitation services on mortality among stroke patients : A Korean nationwide population-based retrospective cohort study
- Trends and disparities in cerebrovascular disease mortality among patients with bronchus and lung cancer in the United States, 1999–2020: a population-based retrospective study
BibTeX
@article{timshina2026alcoholic,
title = {{Alcoholic Cardiomyopathy Mortality in the United States (1999-2024): Trends, Disparities, and Opportunities for Prevention}},
author = {Anuj Timshina and Anukul Subedi and Prabin Duwadee and Paribesh Gyawali and Laxman Wagle},
journal = {Cureus},
year = {2026},
month = oct,
doi = {10.7759/cureus.117430},
url = {https://europepmc.org/article/PMC/PMC13730119},
note = {CC BY},
}
RIS
TY - JOUR
TI - Alcoholic Cardiomyopathy Mortality in the United States (1999-2024): Trends, Disparities, and Opportunities for Prevention
AU - Anuj Timshina
AU - Anukul Subedi
AU - Prabin Duwadee
AU - Paribesh Gyawali
AU - Laxman Wagle
PY - 2026
DA - 2026/10/04
JO - Cureus
DO - 10.7759/cureus.117430
UR - https://europepmc.org/article/PMC/PMC13730119
AB - Aim: This study aimed to characterize long-term US mortality from alcoholic cardiomyopathy (ACM), compare its trajectory with other major cardiomyopathy subtypes, and identify demographic and geographic disparities relevant to cardiovascular prevention. Methods: We conducted a serial cross-sectional analysis of Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) underlying-cause-of-death data from 1999 to 2024. Cardiomyopathy deaths were identified using ICD-10 codes I42.0, I42.1, I42.2, I42.5, I42.6, I42.8, and I42.9. Annual age-adjusted mortality rates (AAMRs) were assessed overall and by sex; age-specific crude death rates (CDRs) were recalculated for ages 15-44, 45-64, and 65-84 years. ACM mortality was also examined by race and state. Results: From 1999 to 2024, AAMRs declined for dilated cardiomyopathy (1.965 to 0.716 per 100,000; -63.6%), unspecified cardiomyopathy (7.196 to 3.155; -56.2%), and other hypertrophic cardiomyopathy (0.450 to 0.228; -49.2%). ACM declined less, from 0.199 to 0.144 (-27.7%), with an increase during the early 2020s. Male ACM AAMR declined from 0.408 to 0.209 but remained nearly fourfold the female rate in 2024 (0.054). Mortality was concentrated among middle-aged and older males; American Indian or Alaska Native individuals had the highest population-based ACM mortality, and Alaska had the highest pooled state AAMR in 2018-2024. Conclusion: ACM showed a smaller long-term mortality reduction than several major cardiomyopathy subtypes and persistent demographic and geographic disparities. Integrating cardiovascular prevention and heart failure care with recognition and treatment of harmful alcohol use may help reduce this potentially modifiable burden.
SN - 2168-8184
ER -